Fabian Lang, MD, Goethe University, Frankfurt, Germany, comments on the tolerability and efficacy of asciminib in the treatment of patients with chronic myeloid leukemia (CML) in the third-line setting, highlighting the importance of improving the outcomes of this patient population and achieving a higher rate of treatment-free remission (TFR). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.